Does adjuvant anti-PD-1 improve survival in real-world stage III melanoma?
Danish Metastatic Melanoma Database shared on LinkedIn:
“DOES ADJUVANT ANTI-PD-1 IMPROVE SURVIVAL IN REAL-WORLD STAGE III MELANOMA?
Excellent poster presentation at ESMO Immuno2024 by PhD candidate and MD Marie Brinch-Møller Weitemeyer. Abstract.
A nationwide study using data from the Danish Metastatic Melanoma Database (DAMMED) and national health registries investigates the real-world impact of adjuvant anti-PD-1 therapy in resected stage IIIA-D melanoma. Patients treated with adjuvant anti-PD-1 were compared to historical untreated patients using propensity score matching.
Key findings (median follow-up: 55 months):
No survival difference observed between unmatched total stage III cohorts before and after adjuvant anti-PD-1 implementation – consistent with findings from Sweden (Hildur Helgadottir et al.).
Authors: Hildur Helgadottir, Lars Ny, Gustav J Ullenhag, Johan Falkenius, Rasmus Mikiver, Roger Olofsson Bagge, Karolin Isaksson
HOWEVER
Longer OS observed in the adjuvant anti-PD-1 treated patients vs matched untreated patients:
4-year OS: 82.7% vs 76.8% (HR 0.67 [95% CI: 0.48–0.95])
Numerical improvement in MSS in the adjuvant anti-PD-1 treated patients vs matched untreated patients:
4-year MSS: 85.8% vs 83.4% (HR 0.76 [95% CI: 0.51–1.12])
A potential survival benefit of adjuvant anti-PD-1 therapy in resected stage III melanoma cannot be excluded.
Longer follow-up may be needed to determine the real-world clinical impact of adjuvant anti-PD-1 therapy. The eagerly awaited survival results from pivotal anti-PD-1 trials vs placebo will provide further context (more here.).”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023